Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier:
NCT00857532
First received: March 5, 2009
Last updated: February 1, 2013
Last verified: February 2013

March 5, 2009
February 1, 2013
January 2009
November 2011   (final data collection date for primary outcome measure)
Mean Cortical Amyloid Burden [ Time Frame: 50-60 min after injection ] [ Designated as safety issue: No ]
Standardized uptake value ratios (SUVR) were calculated and compared between subjects with PD and controls. Subjects with Parkinson's Disease (PD) were stratified into one of three groups based on performance on the age and education adjusted Mattis Dementia Rating Scale (DRS-2). The age and education adjusted DRS-2 ranges from 0 (lowest cognitive function) to 20 (highest cognitive function). SUVR is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum. SUVR values higher than 1 indicate greater amyloid burden in the predefined cortical regions as compared to cerebellum whereas scores less than 1 indicate the opposite. This outcome measure only reports data from the subjects analyzed in this study, the data from normal controls was obtained from a pre-existing database and is not reported here.
Blinded image reading to determine the mean cortical target binding (average SUVR of frontal cortex, temporal cortex, parietal cortex, posterior cingulate cortex and precuneus) in PD patients compared to that of controls. [ Time Frame: ~15 months, following the enrollment of all subjects in the study ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00857532 on ClinicalTrials.gov Archive Site
  • Correlation Between Global Amyloid Burden and Clinical Measures of Cognitive Decline. [ Time Frame: 50-60 min after injection ] [ Designated as safety issue: No ]
    Correlation between amyloid burden (global florbetapir SUVR) and cognitive decline (DRS-2 score) was determined using Spearman's rank order correlation method where SUVR was the dependent variable and the DRS-2 score was the independent variable. This analysis was performed for total DRS-2 score and the five DRS-2 subscale scores. The subscales (score range) are: Attention (0-37), Initiation/Perseveration (0-37), Construction (0-6), Conceptualization (0-39) and Memory (0-25). The total DRS-2 score is the sum of the subscale scores and ranges from 0-144. Higher DRS-2 scores indicate greater cognitive function.
  • Correlation of Florbetapir SUVR With CSF Biomarker Values [ Time Frame: 50-60 min after injection ] [ Designated as safety issue: No ]
    Correlation between amyloid burden (florbetapir SUVR) and cerebrospinal fluid (CSF) biomarker values (amyloid beta, tau and phospho-tau) was determined using Spearman's rank order correlation in a subset of subjects undergoing CSF analysis where SUVR was the dependent variable and CSF biomarker values were the independent variables.
Not Provided
Not Provided
Not Provided
 
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment

The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
Parkinson's Disease
Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
  • 18F-AV-45
  • Amyvid
  • florbetapir
  • Experimental: Normal cognitive performance
    Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
    Intervention: Drug: florbetapir F 18
  • Experimental: Mild cognitive deficits
    Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
    Intervention: Drug: florbetapir F 18
  • Experimental: Severe cognitive impairment
    Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
    Intervention: Drug: florbetapir F 18
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
November 2011
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects may be enrolled if they (inclusion criteria):

    • Are males or females ≥60 years of age
    • Meet research diagnostic criteria for Parkinson's disease:
    • Diagnosis of a parkinsonian syndrome

      • Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions)
      • At least one of the following: muscle rigidity, rest tremor, postural instability not due to visual, vestibular, cerebellar or proprioceptive causes
    • Supportive criteria for diagnosis of PD (two or more required)

      • Unilateral onset of symptoms and persistent asymmetry
      • Rest tremor present
      • Progressive illness
      • Excellent response to levodopa with dyskinesias
      • Levodopa response for 5 years or more
      • Clinical course of 10 years or more
    • Have the ability to lie flat and tolerate a 10 minute PET scan.

Exclusion Criteria:

  • Subjects may not be enrolled if any of the following are present (exclusion criteria):

    • History of repeated strokes, repeated head injury, definite encephalitis
    • Use of neuroleptics at onset of symptoms
    • Sustained remission
    • Strictly unilateral feature persisting > three years after onset
    • Significant supranuclear gaze palsy
    • Cerebellar, pyramidal and early severe autonomic findings
    • Early severe dementia suggesting a diagnosis of dementia with Lewy bodies (DLB)
    • Imaging study showing structural abnormality that could explain parkinsonism
    • Negative response to an adequate levodopa trial
    • Current clinically significant psychiatric disease that prohibits providing informed consent or participation in the study
    • Current clinically significant endocrine or metabolic disease, pulmonary,
    • Women of childbearing potential who are not two or more years post menopausal or surgically sterilized
    • Have received any investigational medications, or have participated in a trial with investigational medications within the last 30 days
Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00857532
18F-AV-45-A12, 5R43NS063607-02
No
Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
  • National Institutes of Health (NIH)
  • National Institute of Neurological Disorders and Stroke (NINDS)
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP